Aficamten: A New Horizon for Hypertrophic Cardiomyopathy Treatment

Cytokinetics' experimental drug Aficamten demonstrates superior improvements in exercise capacity and cardiac function compared to standard care for obstructive hypertrophic cardiomyopathy, with a favorable safety profile across multiple studies.